Published: 05/12/2002, Volume112 No. 5834 Page 8

Thousands of people are still being denied newer drugs that cut side-effects despite National Institute for Clinical Excellence guidance approving the use of atypical schizophrenia medication, according to mental health charity Rethink. Its research says that 210,000 people are eligible for the drugs, but a survey of 302 primary care trusts in England and Wales reveals that 97 per cent knew of the NICE ruling but only 80 per cent had implemented it; 78 per cent say they have experienced financial pressure due to the decision.

www. nice. org. uk